Inhibikase Therapeutics, Inc. 8-K

What Happened
Inhibikase Therapeutics, Inc. announced via an 8-K (Regulation FD disclosure) and accompanying press release dated April 7, 2026, that the first patient has been enrolled in the global Phase 3 IMPROVE-PAH study evaluating IKT-001 for the treatment of pulmonary arterial hypertension (PAH). The company furnished the press release as Exhibit 99.1 to the Form 8-K.

Key Details

• First patient enrolled in the global Phase 3 study named IMPROVE-PAH for IKT-001.
• Announcement made and press release dated April 7, 2026; press release provided as Exhibit 99.1 to the 8-K.
• Item reported on the Form 8-K: 7.01 (Regulation FD Disclosure); the filing also includes exhibits under Item 9.01.

Why It Matters
Enrollment of the first patient signals the formal start and a key clinical milestone for Inhibikase’s Phase 3 program in PAH, advancing IKT-001 toward later-stage development. For investors, this is a material operational update: it confirms progress in the company’s clinical pipeline and is a milestone to monitor for future enrollment updates, trial progress, and eventual readouts. The filing did not include financial results or timeline specifics beyond the enrollment announcement.